Abstract:Cellular senescence is a hallmark of normal aging and aging-related syndromes, including the premature aging disorder Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder caused by a single mutation in the LMNA gene that results in the constitutive expression of a truncated splicing mutant of lamin A known as progerin. Progerin accumulation leads to increased cellular stresses including unrepaired DNA damage, activation of the p53 signaling pathway and accelerated senescence. We previously established that the p53 isoforms ∆133p53 and p53β regulate senescence in normal human cells. However, their role in premature aging is unknown. Here we report that p53 isoforms are expressed in primary fibroblasts derived from HGPS patients, are associated with their accelerated senescence and that their manipulation can restore the replication capacity of HGPS fibroblasts. We found that in near-senescent HGPS fibroblasts, which exhibit low levels of ∆133p53 and high levels of p53β, restoration of Δ133p53 expression was sufficient to extend replicative lifespan and delay senescence, despite progerin levels and abnormal nuclear morphology remaining unchanged. Conversely, Δ133p53 depletion or p53β overexpression accelerated the onset of senescence in otherwise proliferative HGPS fibroblasts. Our data indicate that Δ133p53 exerts its role by modulating full-length p53 (FLp53) signaling to extend the replicative lifespan and promotes the repair of spontaneous progerin-induced DNA double-strand breaks (DSBs). We showed that Δ133p53 dominant-negative inhibition of FLp53 occurs directly at the p21/CDKN1A and miR-34a promoters, two p53 senescence-associated genes. In addition, Δ133p53 expression increased the expression of DNA repair RAD51, likely through upregulation of E2F1, a transcription factor that activates RAD51, to promote repair of DSBs. In summary, our data indicate that Δ133p53 modulates p53 signaling to repress progerin-induced early onset of senescence in HGPS cells. Therefore, restoration of ∆133p53 expression may be a novel therapeutic strategy to treat aging-associated phenotypes of HGPS in vivo.

REGγ Deficiency Promotes Premature Aging Via the Casein Kinase 1 Pathway.

Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging

p53 isoforms regulate premature aging in human cells

REGγ modulates p53 activity by regulating its cellular localization

REGgamma modulates p53 activity by regulating its cellular localization.

Senescence regulation by the p53 protein family.

Linked regulation of genome integrity and senescence-associated inflammation by p53

p53 mutant mice that display early ageing-associated phenotypes

Hsp90β Interacts with MDM2 to Suppress P53‐dependent Senescence During Skeletal Muscle Regeneration

Aging-associated REGγ proteasome decline predisposes to tauopathy

REGγ Mediated Regulation of P21waf/cip1, P16ink4a and P14arf/p19arf in Vivo

Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program

DRG2 Accelerates Senescence via Negative Regulation of SIRT1 in Human Diploid Fibroblasts

Gain-of-Function p53N236S Mutation Drives the Bypassing of HRasV12-Induced Cellular Senescence via PGC–1α

Upregulation of GSK3β Contributes to Brain Disorders in Elderly REGγ-knockout Mice

REGγ Mediated Regulation of p21 Waf/Cip1 , p16 INK4a and p14 ARF /p19 ARF in Vivo

Upregulation of GSK3 β Contributes to Brain Disorders in Elderly REG γ -knockout Mice

The REGγ-Proteasome Regulates Spermatogenesis Partially by P53-PLZF Signaling

Differential Regulation Of The Reg Gamma-Proteasome Pathway By P53/Tgf-Beta Signalling And Mutant P53 In Cancer Cells

The Dysfunctional MDM2–p53 Axis in Adipocytes Contributes to Aging-Related Metabolic Complications by Induction of Lipodystrophy